Galapagos reaches milestone in immuno-inflammation alliance with GSK
Galapagos has reached a milestone in its immuno-inflammation alliance with GlaxoSmithKline (GSK) by delivering a fifth pre-clinical drug candidate.
Galapagos CEO Onno van de Stolpe said the company has identified five candidate drugs of which two have been in-licensed by GSK to date, since the start of the alliance in 2006.
"We hope that more programs from this alliance may enter the clinic," Onno van de Stolpe added.
In 2006 the companies entered into an agreement to discover and develop disease-modifying drugs for GSK's global R&D organization.
Under the agreement, Galapagos is eligible to earn more than €200m in total milestone payments in addition to royalties from GSK.
Latest News
Related News
Related Sectors
Drug Research> Drug Discovery & Development
Related Dates
2013> January
Related Industries
Pharmaceuticals and Healthcare> Services> Technology> Drug Discovery
Drug Research> Drug Discovery & Development
Related Dates
2013> January
Related Industries
Pharmaceuticals and Healthcare> Services> Technology> Drug Discovery
Related Insight
Suppliers Directory
Polygon Medical Animation - 3D Medical Animation, Illustration and Interactive
Polygon is the full-service global provider of high-end MOA mechanism of action 3D medical animation and Illustration for the Pharma and Biotech industry, as well as educational institutes worldwide.
Drug Research > Drug Discovery & Development > Suppliers
Bachem - Process Development and Manufacturing of Peptides and Complex Organic Molecules as APIs
Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialised in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes.
Drug Research > Drug Discovery & Development > Suppliers
4-Antibody - Therapeutic Antibody Technology
4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform, which is generating an emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in-vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates.
Drug Research > Drug Discovery & Development > Suppliers
Logopharm - Membrane Proteomics
LOGOPHARM GmbH provides specialised services in proteomic target and biomarker R&D with a strong focus on membrane proteins and antibodies.
Drug Research > Drug Discovery & Development > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Discovery & Development Intelligence
Fluorescent 2-Hybrid (F2H®) Assay
Published by ChromoTek
Drug Research > Drug Discovery & Development > White Papers
Win with Networked Drug Development Alliances
Published by INC Research
Drug Research > Drug Discovery & Development > White Papers
Certainty Within Clinical Development
Published by CYNCRON
Drug Research > Drug Discovery & Development > White Papers
CRM for Life Sciences
Published by NNIT
Drug Research > Drug Discovery & Development > White Papers
Buy the latest industry research online today!
African Pharmaceutical Directory 2013
API research into pharmaceutical companies and corporations Buy online from $200
API research into pharmaceutical companies and corporations Buy online from $200

Comments may be moderated for spam, obscenities or defamation.